A Study of SDX-7320 with Eribulin for Metastatic Triple-Negative Breast Cancer
This study is investigating if combining the drug SDX-7320 with standard chemotherapy, eribulin, is an effective and safe treatment for people with metastatic triple-negative breast cancer (TNBC). TNBC is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2 protein. The study will compare this combination to eribulin alone. Researchers will measure changes in insulin resistance scores (HOMA-IR) after one year to see how well the treatment works. You may be eligible if you are an adult with TNBC that is HER2-negative.
- Study design
- This study plans to enroll 55 participants. The first 15 participants will receive SDX-7320 and eribulin, and then the remaining 40 participants will be randomly assigned to a treatment group.
- What's involved
- You would receive eribulin intravenously (into a vein) on days 1 and 8 of a 21-day cycle, and SDX-7320 subcutaneously (under the skin) every 14 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will measure changes in insulin resistance scores (HOMA-IR) at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT05570253
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Recruiting
PHASE2Ages 18+InterventionalTreatmentMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~55 participants
Updated 2026-08-05 on ClinicalTrials.gov
What's tested:EribulinSDX-7320Placebo
At a glance
Recruiting sites
10 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
change in insulin resistance scores (HOMA-IR)
Measured over 1 year
Conditions
Where it's being run
10 sites across 4 statesNew Jersey4
New York4
Florida1
Georgia1
Study leadership
- Sherry Shen, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male or female with histologically and/or cytologically confirmed diagnosis of triple-negative metastatic breast cancer defined as estrogen and progesterone receptor staining ≤10%; and HER2-negative defined as IHC 0 to 1+ at enrolling institution (note: if IHC is equivocal, non-amplified status by FISH is acceptable)
Advanced (local regionally recurrent, not amenable to curative therapy or surgery) or metastatic stage with up to 2 prior lines of therapy in the advanced or metastatic setting
Received prior anthracycline and taxane chemotherapy in the neoadjuvant, adjuvant, or metastatic settings and considered appropriate for treatment with single agent eribulin OR was otherwise ineligible to receive anthracycline and/or taxane per treating physician OR patients with de novo metastatic disease.
Evidence of metabolic dysfunction defined as HbA1c \> 5.5 and/or BMI ≥ 30 kg/m\^2
Measurable disease per the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), OR at least one evaluable, predominantly lytic bone lesion
Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≤1.
Adult ≥18 at the time of informed consent and has provided written informed consent before the performance of any study-related activities and according to local guidelines.
Adequate bone marrow and organ function as defined by the following laboratory values (as assessed by local laboratory for eligibility):
Absolute neutrophil count (ANC) ≥ 1,000 µL
Platelet count ≥ 140,000 µL
Hemoglobin ≥9.0 g/dL:
Calcium (corrected for serum albumin) and magnesium ≤ Grade 1 according to National Cancer Institute (NCI) Common Terminology
Calculate Corrected Calcium if the albumin and/or serum calcium are not within normal limits: Corrected Calcium= Serum Calcium + 0.8 x \[(Normal Albumin) - Patient Albumin\] Normal Albumin value = 4.4g/dL Criteria for Adverse Events (CTCAE), version 5.0, and not considered by the Investigator to be clinically significant
Potassium within normal limits, with or without correction with supplements.
In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×the upper limit of normal (ULN). If the patient has liver metastases, ALT and AST ≤5×ULN.
Total bilirubin ≤1.5×ULN except for patient with Gilbert's syndrome who may only be included if the total bilirubin is ≤3.0×ULN or direct bilirubin ≤1.5×ULN
Creatinine ≤1.5 mg/dL.
Patient is, in the treating Investigator's opinion, willing and able to comply with the study requirements, including the ability to fast prior to treatment days.
If sexually active female of childbearing potential, willing to use a contraception method listed below:
Oral, intravaginal, or transdermal combined (estrogen and progesterone containing) hormonal contraception
Oral, injectable, or implantable progesterone-only hormonal contraception
Intrauterine device (IUD)
Intrauterine hormone-releasing system (IUS)
Bilateral tubal occlusion
Vasectomized partner with documentation of successful vasectomy.
Complete abstinence from heterosexual intercourse
If a sexually active male, willing to use barrier contraception (condoms)
Exclusion
Three or greater prior lines of therapy for metastatic TNBC
Known primary brain malignancy, brain metastases or active CNS pathology, any of which as determined by the treating Investigator
Currently participating in a study of an investigational agent
Body mass index \< 18.5 kg/m2
Known hypersensitivity to SDX-7320 or eribulin
Established diagnosis of diabetes mellitus type I or uncontrolled or insulin-dependent type II. Uncontrolled is defined as fasting blood glucose \>140 mg/dL and/or HbA1c ≥8%
Use of combination antihyperglycemic therapy (single agent metformin on stable dose for at least 3 months prior to enrollment is allowable)
Concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, nonmelanomatous skin cancer or curatively resected cervical cancer.
Uncontrolled human immunodeficiency virus (HIV) infection. (Testing is not mandatory.)
Evidence of uncontrolled active Hepatitis B or C infection
History of Stevens-Johnson Syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), or other severe medication-related cutaneous reactions.
Any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate patient participation in the clinical study (e.g., chronic active hepatitis, severe hepatic impairment).
Clinically significant, uncontrolled heart disease and/or recent cardiac events including any of the following:
History of angina pectoris, coronary artery bypass graft (CABG) symptomatic pericarditis, or myocardial infarction within 6 months prior to study entry.
History of documented congestive heart failure (New York Heart Association functional classification III-IV).
Documented cardiomyopathy.
Left ventricular ejection fraction (LVEF) \<45%, as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).
History of any cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle block, high grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.
Uncontrolled hypertension, defined by a systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication(s) is allowed prior to screening
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome or any of the following: risk factors for torsades de pointe including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure or history of clinically significant/symptomatic bradycardia; concomitant medications with a known risk to prolong the QT interval and known to cause torsades de pointe that cannot be discontinued or replaced by safe alternative medications.
Bradycardia (heart rate less than 50 at rest), by electrocardiogram (ECG) or pulse.
Inability to determine the QT interval on the ECG (i.e., unreadable or not interpretable) or corrected QT (QTcF) \>450 msec for males and \>470 msec for females (using Fridericia's correction) during Screening, based on the mean of triplicate ECGs
Currently receiving any of the following medications and cannot be discontinued 7 days prior to the start of the treatment: Medications with a known risk to prolong the QT interval or induce Torsade de Pointes (TdP). CredibleMeds list of drugs known to cause TdP may be used as a reference for this study to determine which drugs are prohibited using the following link: https://crediblemeds.org/new-drug-list or a crediblemeds mobile application.
Participation in a prior investigational study within 14 days prior to the start of the study treatment or within 5 half-lives of study drug, whichever is longer.
History of acute pancreatitis within 1 year of Screening or past medical history of chronic pancreatitis
Pregnant patients
What this trial measures
- change in insulin resistance scores (HOMA-IR)1 year
The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) is a validated tool for the assessment of insulin resistance.87 HOMA-IR is calculated as follows: fasting serum insulin (μU/mL) × fasting plasma glucose (mmol L -1 )/22.5).